**Pathways**

anticancer activity. International Journal of Cancer. 2015;136:2228–2240. DOI: 10.1002/

[203] Slager J, Tyler B, Shikanov A, Domb AJ, Shogen K, Sidransky D, et al. Local controlled delivery of anti‐neoplastic RNAse to the brain. Pharmaceutical Research. 2009;26:1838–

ijc.29258

168 Anti-cancer Drugs - Nature, Synthesis and Cell

1846. DOI: 10.1007/s11095‐009‐9893‐3

Satyajit Das, Jaydip Biswas and Immune Pathways

Soumitra Kumar Choudhuri

Additional information is available at the end of the chapter Additional information is available at the end of the chapter

Potential Anticancer Drugs Targeting

Satyajit Das, Jaydip Biswas and Soumitra Kumar Choudhuri

http://dx.doi.org/10.5772/65352

#### Abstract

Studies on the tumor microenvironment reveal that infiltration or induction of tumorassociated immune regulatory populations at the local tumor site is strongly associated with severe immunosuppression as well as worse prognosis of patients. Despite major advances in cancer immunotherapy, most of the therapeutic agents often fail to break negative immunosuppressive network to trigger anticancer immunity, leading to tumor progression and metastasis. Therefore, emergence of potent immunostimulatory agents is of great clinical importance. Emerging evidence suggests that metal chelates of Schiff bases hold the promise to overcome tumor-associated immunosuppression by inhibiting or subverting suppressive immune population toward pro-immunogenic type and thus can be used clinically for immunotherapy of different types of cancers.

Keywords: immunosuppression, tumor microenvironment, antitumor response, reactive oxygen species (ROS), tumor-associated macrophage (TAM), myeloid-derived suppressor cells (MDSC), regulatory T cell (Treg)
